Tebentafusp in metastatic uveal (ocular) melanoma: A comprehensive review

“

This immunotherapy, which directly engages the patient’s immune system to target and destroy tumour cells, has set a new standard for treatment efficacy in this rare and aggressive form of cancer. Combining a T-cell receptor with an anti-CD3 single-chain variable fragment, its bi-specific mechanism harnesses the body’s natural defences. This novel approach has shown superior overall survival results in clinical trials compared to treatments such as pembrolizumab. Despite these advances, the use of tebentafusp is limited by genetic factors, particularly the requirement for HLA-A*02:01 expression, which is absent in a significant proportion of the target population. This limitation restricts the widespread use of this therapy and highlights the need for genetic screening prior to treatment. In addition, while the adverse effects associated with tebentafusp, such as CRS and skin reactions, are manageable and tend to decrease over time, they require careful monitoring and management, which could complicate treatment protocols and patient compliance. In light of these findings, it is clear that while tebentafusp represents a significant leap forward in the treatment of mUM, there is a critical need for further research. While tebentafusp has already demonstrated a survival benefit in metastatic uveal melanoma and is approved in this setting, there are currently no approved or standard adjuvant therapies for patients at high risk of relapse after definitive local treatment of their primary tumour. This is particularly concerning given that approximately 50% of patients will eventually develop metastatic disease despite successful surgery or radiotherapy. The EORTC ATOM trial (NCT06246149) is the first and only active phase 3 trial evaluating adjuvant tebentafusp in this population. It aims to determine whether early intervention with this T-cell receptor-based therapy can reduce the risk of relapse compared to observation alone. This is a clinically important question, as relapse in uveal melanoma is typically incurable and associated with poor survival. Future studies should focus on overcoming the genetic limitations of treatment applicability by developing strategies that could extend the benefits of tebentafusp to a broader patient base. In addition, the refinement of combination therapies that can synergise with the mechanism of tebentafusp could mitigate its limitations and enhance its efficacy. Research into biomarkers to predict treatment response and tailor therapies to individual patients will also be key to advancing the personalized medicine approach in this field.

”